CARGO Therapeutics (NASDAQ:CRGX) versus JATT Acquisition (NYSE:JATT) Head to Head Comparison

CARGO Therapeutics (NASDAQ:CRGX) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CARGO Therapeutics and JATT Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	0	0	8	0	3.00
JATT Acquisition	0	0	0	0	0.00

CARGO Therapeutics currently has a consensus target price of $30.33, suggesting a potential upside of 71.67%. Given CARGO Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe CARGO Therapeutics is more favorable than JATT Acquisition.

Profitability

This table compares CARGO Therapeutics and JATT Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-38.16%	-33.94%
JATT Acquisition	N/A	-49.58%	2.84%

Insider and Institutional Ownership

93.2% of CARGO Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares CARGO Therapeutics and JATT Acquisition”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CARGO Therapeutics	N/A	N/A	-$98.15 million	($4.26)	-4.15
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A

Summary

CARGO Therapeutics beats JATT Acquisition on 5 of the 8 factors compared between the two stocks.

About CARGO Therapeutics

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.